Soluble epidermal growth factor receptor (EGFR) and HER-2 monitoring in a Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell lung cancer (NSCLC)
2004 ◽
Vol 22
(14_suppl)
◽
pp. 7090-7090
2004 ◽
Vol 22
(14_suppl)
◽
pp. 7090-7090
2017 ◽
Vol Volume 10
◽
pp. 1757-1766
◽
2018 ◽
Vol 56
(2)
◽
pp. 179-183
◽